A highly conserved tyrosine residue at codon 845 within the kinase domain is not required for the transforming activity of human epidermal growth factor receptor-Reference-Cited by-同舟云学术

A highly conserved tyrosine residue at codon 845 within the kinase domain is not required for the transforming activity of human epidermal growth factor receptor

Published:1992-07 Issue:2 Volume:186 Page:768-774
ISSN:0006-291X
Container-title:Biochemical and Biophysical Research Communications
language:en
Short-container-title:Biochemical and Biophysical Research Communications

Author:

Gotoh Noriko,Tojo Arinobu,Hino Masayuki,Yazaki Yoshio,Shibuya Masabumi

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry,Biophysics

Reference28 articles.

1. GROWTH FACTOR RECEPTOR TYROSINE KINASES

2. Signal transduction by receptors with tyrosine kinase activity

3. Self-phosphorylation enhances the protein-tyrosine kinase activity of the epidermal growth factor receptor.

4. Alteration of epidermal growth factor receptor activity by mutation of its primary carboxyl-terminal site of tyrosine self-phosphorylation.

5. Kinetic parameters of the protein tyrosine kinase activity of EGF-receptor mutants with individually altered autophosphorylation sites.

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Computational Analysis of Activation of Dimerized Epidermal Growth Factor Receptor Kinase Using the String Method and Markov State Model;Journal of Chemical Information and Modeling;2024-04-26

2. Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases;Pharmacological Research;2024-01

3. Epidermal Growth Factor Receptor Inhibiting 4‐Aminoquinazolines as Promising Anticancer Agents: A Patent Review (2000‐Present);ChemistrySelect;2023-06-14

4. Kinase Inhibitors Involved in the Regulation of Autophagy: Molecular Concepts and Clinical Implications;Current Medicinal Chemistry;2023-04

5. Potential of Heterocyclic Compounds as EGFR-TK Inhibitors in Cancer Therapy;Novel Technologies in Biosystems, Biomedical & Drug Delivery;2023